These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31344662)

  • 41. Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: a case control study.
    Xing X; Gan Y; Mo W; Zhang J; Wang N; Zhang K; Ma K; Zhang L; Ma L; Lu D; Li Y; He J
    Clin Rheumatol; 2024 Mar; 43(3):1145-1154. PubMed ID: 38326675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.
    Yen TH; Tseng CW; Wang KL; Fu PK
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
    Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
    Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
    So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
    Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case-Control Study.
    Weng C; Ding Z; Zhou Y; Yang Q; Xue L; Zhang L; Wang G; Liu Z
    Rheumatol Ther; 2023 Jun; 10(3):635-648. PubMed ID: 36802052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
    J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
    So H; Wong VTL; Lao VWN; Pang HT; Yip RML
    Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
    J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New aspects of clinical and immunological characteristics in patients with anti-asparaginyl tRNA synthetase (anti-KS) autoantibody.
    Hosono Y; Ishii A; Izumi Y; Sasaki N; Nogi S; Yamada C; Sato S
    Mod Rheumatol; 2023 Dec; 34(1):122-128. PubMed ID: 36691996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
    He C; Li W; Xie Q; Yin G
    Front Immunol; 2021; 12():820163. PubMed ID: 35116041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical features and prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease in Chinese patients.
    Lian L; Tong JJ; Xu SQ
    Immun Inflamm Dis; 2023 Jun; 11(6):e882. PubMed ID: 37382274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
    Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
    Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case].
    Girard C; Vincent T; Bessis D
    Ann Dermatol Venereol; 2013 Oct; 140(10):628-34. PubMed ID: 24090894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2011 Sep; 105(9):1380-7. PubMed ID: 21632230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease.
    Ito M; Kaise S; Suzuki S; Kazuta Y; Sato Y; Miyata M; Nishimaki T; Nakamura N; Kasukawa R
    Clin Rheumatol; 1999; 18(6):462-7. PubMed ID: 10638771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic value of HRCT in myositis-associated interstitial lung disease.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Aihara K; Ikezoe K; Watanabe K; Taguchi Y; Hatta K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2013 May; 107(5):745-52. PubMed ID: 23485097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
    Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
    J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An approach to the development of interstitial lung disease in dermatomyositis: a study of 230 cases in China.
    Wu H; Geng D; Xu J
    J Int Med Res; 2013 Apr; 41(2):493-501. PubMed ID: 23569020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.